ELOXX PHARMACEUTICALS, INC.: 10-Q filed 2017-02-10
What ELOXX PHARMACEUTICALS, INC. reported in its quarterly report filed 2017-02-10 (fiscal Q2 2017): 26 published measures, 72 facts as tagged in accession 0001144204-17-007403.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-02-10
- Fiscal period
- fiscal Q2 2017
- Accession
- 0001144204-17-007403 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ELOXX PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 5,806,597 | USD | |
| At 2016-06-30 | 9,225,952 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 2,964,198 | USD | |
| At 2016-06-30 | 4,665,294 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 2,842,399 | USD | |
| At 2016-06-30 | 4,560,658 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 149,193 | USD | |
| At 2016-06-30 | 810,808 | USD | |
| At 2015-12-31 | 2,366,573 | USD | |
| At 2015-06-30 | 3,334,626 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -789,831 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -1,723,408 | USD | 184 |
| 2015-10-01 to 2015-12-31 | -3,855,420 | USD | 92 |
| 2015-07-01 to 2015-12-31 | -4,036,163 | USD | 184 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-12-31 | 0 | USD | 184 |
| 2015-07-01 to 2015-12-31 | 0 | USD | 184 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | -117,378,750 | USD | |
| At 2016-06-30 | -115,630,059 | USD |
Income tax expense or benefit
Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -400,000 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -1,040,000 | USD | 184 |
| 2015-10-01 to 2015-12-31 | 0 | USD | 92 |
| 2015-07-01 to 2015-12-31 | 0 | USD | 184 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 67,045 | USD | |
| At 2016-06-30 | 92,554 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -3,056 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 5,149 | USD | 184 |
| 2015-10-01 to 2015-12-31 | 64,357 | USD | 92 |
| 2015-07-01 to 2015-12-31 | 88,833 | USD | 184 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -1,507,487 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -3,718,019 | USD | 184 |
| 2015-10-01 to 2015-12-31 | -3,758,106 | USD | 92 |
| 2015-07-01 to 2015-12-31 | -4,909,462 | USD | 184 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 199,752 | USD | |
| At 2016-06-30 | 982,628 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 764,198 | USD | |
| At 2016-06-30 | 368,991 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 193,935 | USD | |
| At 2016-06-30 | 90,305 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 207,376 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 487,616 | USD | 184 |
| 2015-10-01 to 2015-12-31 | 594,504 | USD | 92 |
| 2015-07-01 to 2015-12-31 | 1,196,087 | USD | 184 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 20,736,847 | shares | |
| At 2016-06-30 | 20,496,385 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 120,011,526 | USD | |
| At 2016-06-30 | 119,983,399 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 0 | USD | |
| At 2016-06-30 | 99,728 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 270,263 | USD | |
| At 2016-06-30 | 256,376 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 50,559 | USD | |
| At 2016-06-30 | 171,820 | USD |
Pre-tax income or loss from continuing operations
Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -1,189,831 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -2,763,408 | USD | 184 |
| 2015-10-01 to 2015-12-31 | -3,855,420 | USD | 92 |
| 2015-07-01 to 2015-12-31 | -4,036,163 | USD | 184 |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -805,612 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -1,748,691 | USD | 184 |
| 2015-10-01 to 2015-12-31 | -3,869,534 | USD | 92 |
| 2015-07-01 to 2015-12-31 | -4,198,646 | USD | 184 |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -805,612 | USD | 92 |
| 2016-07-01 to 2016-12-31 | -1,748,691 | USD | 184 |
| 2015-10-01 to 2015-12-31 | -3,869,534 | USD | 92 |
| 2015-07-01 to 2015-12-31 | -4,198,646 | USD | 184 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 300,111 | USD | 92 |
| 2016-07-01 to 2016-12-31 | 780,131 | USD | 184 |
| 2015-10-01 to 2015-12-31 | 401,102 | USD | 92 |
| 2015-07-01 to 2015-12-31 | 988,375 | USD | 184 |
Deferred income tax expense or benefit
The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-12-31 | -1,040,000 | USD | 184 |
| 2015-07-01 to 2015-12-31 | 0 | USD | 184 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-07-01 to 2016-12-31 | 103,630 | USD | 184 |
| 2015-07-01 to 2015-12-31 | -168,529 | USD | 184 |
Inspect the source
- Entity
- ELOXX PHARMACEUTICALS, INC. / CIK 0001035354
- Captured
- 2026-09-20T05:15:09.498Z
- SEC response SHA-256
b351a9ed06ee3e6f1d738bbdb3852b866526fe561e11a7ffd4a81bc43bb27195
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001035354.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))